16
Participants
Start Date
May 31, 2014
Primary Completion Date
March 31, 2018
Study Completion Date
March 31, 2018
Bevacizumab
Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
Magnetic Resonance Spectroscopy (MRS)
Subjects will have MRS prior to BZ-SRS.
Border Zone Stereotactic Radiosurgery (BZ-SRS)
The 'border zone' of the tumor will be targeted by SRS in a single session.
University of Pittsburgh, Pittsburgh
Collaborators (1)
Genentech, Inc.
INDUSTRY
Ajay Niranjan
OTHER